ABSTRACT
Objective To explore the value of metagenomic next-generation sequencing (mNGS) in the diagnosis and treatment of severe pneumonia after renal transplantation .Methods A total of 38 patients with severe pneumonia after renal transplantation from October 2017 to December 2018 were selected and divided into experimental group (A ,n= 15)and control group (B ,n= 23) based upon whether mNGS of bronchoalveolar lavage fluid was employed for detecting pathogenic microorganisms .Positive rate ,clinical acceptance rate ,hospitalization time ,hospitalization expenses and 28-day mortality rate of two methods were compared .Results Positive rate and clinical acceptance rate of mNGS were higher in experimental group than those in traditional experimental and control groups ( P < 0 .05 ) . Hospitalization time , hospitalization expenses and 28-day mortality of experimental group were lower than those of control group (P< 0 .05) .No significant inter-group difference existed in 90-day mortality (P> 0 .05) .Conclusions For patients with severe pneumonia after renal transplantation , mNGS of bronchoalveolar lavage fluid can improve positive rate of etiological diagnosis and clinical acceptance rate and reduce hospitalization time , hospitalization expenses and 28-day mortality .